670 | OUTCOME OF SECOND‐LINE AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA PATIENTS: REAL‐WORLD ANALYSIS IN THE DACH AREA (GERMANY, AUSTRIA, SWITZERLAND)

Documenti analoghi

• 837 | AXICABTAGENE CILOLEUCEL CAR T‐CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL B‐CELL LYMPHOMA
  di: I. E. Karsten, et al.
  Pubblicazione: (2025)
• 343 | A PILOT STUDY OF AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
  di: C. Jacobson, et al.
  Pubblicazione: (2025)
• Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
  di: Philipp Berning, et al.
  Pubblicazione: (2024)
• Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real‐World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T‐Cell Era
  di: Enver Aydilek, et al.
  Pubblicazione: (2026)
• 460 | CIRCULATING CAR T‐CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH R/R AGGRESSIVE B‐CELL LYMPHOMAS AND ITS ASSOCIATION TO TREATMENT OUTCOME
  di: L. Olsson Werne, et al.
  Pubblicazione: (2025)